2515463-86-0

Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research[1][2][3][4][5].

[1] Bruce A C Cree, et al. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022 Jun 1;35(3):262-270. DOI:10.1097/WCO.0000000000001063
[2] Vermersch P, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. N Engl J Med. 2024 Feb 15;390(7):589-600. DOI:10.1056/NEJMoa2309439
[3] Carvalho T. Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis. Nat Med. 2023 Aug;29(8):1882-1883. DOI:10.1038/d41591-023-00060-4
[4] Weiskorn J, et al. Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes. Horm Res Paediatr. 2024 Apr 30:1-8. DOI:10.1159/000539120
[5] Maddaloni E, et al. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2024 Apr;33(4):303-318. DOI:10.1080/13543784.2024.2326036